ClinicalTrials.gg
CompletedNCT00089635Updated Nov 7, 2022Results posted

Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer

A Phase 2 interventional study of Panitumumab in Colorectal Cancer and Metastases, sponsored by Amgen. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-11-07.

Sponsored by Amgen · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
203
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 90 studies testing panitumumab in Colorectal Neoplasms — 7 open to participants now, 12 under way, 3 of them phase 3. Panitumumab · Colorectal Neoplasms.

Enrollment
20th of 88
203 · median 70
Started
2004
with 3 others
Phase 2
60 of 90
3 open now
Registered
4th of 90
by date
Lead sponsor
20 of 90
Amgen

Among the 90 studies testing panitumumab in Colorectal Neoplasms, this one is the 20th largest by enrollment of the 88 interventional ones that give a count, is one of 4 that started in 2004, is one of 60 in phase 2, and was the 4th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

7 of the 90 studies testing panitumumab in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About panitumumab

Panitumumab: first FDA approval 2006 (VECTIBIX), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 90 studies testing panitumumab in Colorectal Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to determine that panitumumab will have clinically meaningful anti-tumor activity in patients with metastatic colorectal cancer who have developed progressive disease or relapsed while on or after prior fluoropyrimidine, irinotecan and oxaliplatin chemotherapy.

03

Conditions studied

  • Colorectal Cancer
  • Metastases

Keywords

  • Colon, Rectal Cancer
  • ABX-EGF, Panitumumab, EGFr
  • Immunex, Abgenix, Amgen
  • Metastatic Colorectal Cancer
  • Vectibix
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pathologic diagnosis of colorectal adenocarcinoma (diagnostic tissue obtained by tissue )
  • colorectal carcinoma
  • of 0, 1 or 2
  • Documented evidence of disease progression during, or following treatment, with fluoropyrimidine, irinotecan and oxaliplatin chemotherapy for metastatic colorectal cancer
  • Radiographic documentation of disease progression during or within 6 months following the most recent chemotherapy regimen is required
  • Bidimensionally
  • Tumor expressing low to negative levels of epidermal growth factor receptor (EGFr) by immunohistochemistry
  • At least 2 but no more than 3 prior chemotherapy regimens for metastatic colorectal cancer
  • Adequate hematologic, renal and hepatic function

Exclusion criteria

Exclusion Criteria:

  • Symptomatic requiring treatment
  • Patient with a history of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial pneumonitis or pulmonary fibrosis
  • Use of systemic chemotherapy or radiotherapy within 30 days before enrollment
  • Prior anti-EGFr antibody therapy with the exception of the small molecule EGFr tyrosine kinase inhibitors, which are permitted
  • Prior anti-tumor therapies including prior experimental agents or approved anti-tumor small molecules and biologics of short (less than 1 week) serum half-life within 30 days before enrollment, or prior experimental or approved proteins within 6 weeks before enrollment
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
203 participants (actual)

Study arms

  • Experimental
    Panitumumab

    Panitumumab was administered by intravenous (IV) infusion at a dose of 6 mg/kg once every 2 weeks until participants developed progressive disease, were unable to tolerate investigational product, or discontinued for other reasons.

    Drug: Panitumumab

Interventions

  • Administered by intravenous infusion

    Also known as: ABX-EGF, Vectibix®

06

What researchers measure

Primary outcomes

  1. Objective Tumor Response Through Week 16

    Confirmed objective tumor response was defined as a complete response or partial response from enrollment through Week 16. Tumor response was monitored, beginning at Week 8, per a modified version of the World Health Organization (WHO) criteria for tumor response and progression by an independent review committee central assessment. Complete response was defined per modified WHO criteria as disappearance of all lesions (index and non-index). Partial response was defined as ≥ 50% decrease from Baseline in the sum of the products of the longest diameters (SPD) of index lesions. Scans were required to confirm a complete or partial response no earlier than 4 weeks from the time a response of complete or partial response was first documented.

    Time frame: From enrollment through Week 16

  2. Duration of Response

    Kaplan-Meier estimate of time time from first objective response to first observed progression of disease or death if the death was due to disease progression (whichever comes first) among participants who had a response at any time on study. Participants who responded and did not progress while on study or who died for reasons other than disease progression while on study were censored at their last evaluable assessment date.

    Time frame: From enrollment until the data cut-off date of 22 December 2006. The median follow-up time was 36 weeks.

Secondary outcomes

  1. Objective Tumor Response Throughout the Study

    Confirmed objective tumor response was defined as a complete response or partial response from enrollment through to the data cut-ff date. Tumor response was monitored, beginning at Week 8, per a modified version of the World Health Organization (WHO) criteria for tumor response and progression by an independent review committee central assessment. Complete response was defined per modified WHO criteria as disappearance of all lesions (index and non-index). Partial response was defined as ≥ 50% decrease from Baseline in the sum of the products of the longest diameters (SPD) of index lesions. Scans were required to confirm a complete or partial response no earlier than 4 weeks from the time a response of complete or partial response was first documented.

    Time frame: From enrollment until the data cut-off date of 22 December 2006. The median follow-up time was 36 weeks.

  2. Time to Initial Objective Response

    Time from date of enrollment to first objective response; participants with stable disease at their last evaluable assessment date were censored at this date and participants with progressive disease while on study were censored after the last response was observed for all participants.

    Time frame: From enrollment until the data cut-off date of 22 December 2006. The median follow-up time was 36 weeks.

  3. Progression-free Survival Time

    Kaplan-Meier estimate of median time from date of enrollment to date of first observed progression or death (whichever comes first); participants who did not progress while on study and did not die while on study were censored at their last evaluable assessment date.

    Time frame: From enrollment until the data cut-off date of 22 December 2006. The median follow-up time was 36 weeks.

  4. Time to Disease Progression

    Kaplan-Meier estimate of median time from date of enrollment to date of first observed progression or death date if the death was due to disease progression (whichever comes first); participants who have not progressed while on study or died for reasons other than disease progression while on study were censored at their last evaluable assessment date.

    Time frame: From enrollment until the data cut-off date of 22 December 2006. The median follow-up time was 36 weeks.

  5. Time to Treatment Failure

    Kaplan-Meier estimate of median time from date of enrollment to date decision was made to end the treatment phase for any reason; participants who complete the treatment phase or who remain in the treatment phase at the completion of the study were censored at this time.

    Time frame: From enrollment until the data cut-off date of 22 December 2006. The median follow-up time was 36 weeks.

  6. Duration of Stable Disease

    Kaplan-Meier estimate of median time from date of enrollment to date of first observed progression or death date if the death was due to disease progression (whichever comes first); in those participants who had a best response of stable disease. Stable Disease is defined as neither sufficient shrinkage of index lesions to qualify for a partial response nor sufficient increase to qualify for progressive disease taking as reference the nadir sum of the products of the longest diameters since the treatment started.

    Time frame: From enrollment until the data cut-off date of 22 December 2006. The median follow-up time was 36 weeks.

  7. Overall Survival

    Kaplan-Meier estimate of time to death from any cause; participants who had not died while on study or were lost to follow-up were censored at their last contact date.

    Time frame: From enrollment until the data cut-off date of 22 December 2006. The median follow-up time was 36 weeks.

07

Results

Posted Dec 5, 2013

Participant flow

Participants were enrolled from 11 August 2004 through 2 August 2006

Participant flow — Overall Study
MilestonePanitumumab
Started203
Completed160
Not completed43
Withdrew: Adverse event2
Withdrew: Death17
Withdrew: Disease progression12
Withdrew: Lost to follow-up3
Withdrew: Withdrawal by subject6
Withdrew: Ineligibility determined1
Withdrew: Other2

Outcome measures

PrimaryObjective Tumor Response Through Week 16

Confirmed objective tumor response was defined as a complete response or partial response from enrollment through Week 16. Tumor response was monitored, beginning at Week 8, per a modified version of the World Health Organization (WHO) criteria for tumor response and progression by an independent review committee central assessment. Complete response was defined per modified WHO criteria as disappearance of all lesions (index and non-index). Partial response was defined as ≥ 50% decrease from Baseline in the sum of the products of the longest diameters (SPD) of index lesions. Scans were required to confirm a complete or partial response no earlier than 4 weeks from the time a response of complete or partial response was first documented.

Time frame:
From enrollment through Week 16
Reported as:
Number · participants
Objective Tumor Response Through Week 16
participantsPanitumumab
Objective Tumor Response Through Week 166
PrimaryDuration of Response

Kaplan-Meier estimate of time time from first objective response to first observed progression of disease or death if the death was due to disease progression (whichever comes first) among participants who had a response at any time on study. Participants who responded and did not progress while on study or who died for reasons other than disease progression while on study were censored at their last evaluable assessment date.

Time frame:
From enrollment until the data cut-off date of 22 December 2006. The median follow-up time was 36 weeks.
Reported as:
Median · weeks
Duration of Response
weeksPanitumumab
Duration of Response22.2 (16.1 to 28.4)
SecondaryObjective Tumor Response Throughout the Study

Confirmed objective tumor response was defined as a complete response or partial response from enrollment through to the data cut-ff date. Tumor response was monitored, beginning at Week 8, per a modified version of the World Health Organization (WHO) criteria for tumor response and progression by an independent review committee central assessment. Complete response was defined per modified WHO criteria as disappearance of all lesions (index and non-index). Partial response was defined as ≥ 50% decrease from Baseline in the sum of the products of the longest diameters (SPD) of index lesions. Scans were required to confirm a complete or partial response no earlier than 4 weeks from the time a response of complete or partial response was first documented.

Time frame:
From enrollment until the data cut-off date of 22 December 2006. The median follow-up time was 36 weeks.
Reported as:
Number · participants
Objective Tumor Response Throughout the Study
participantsPanitumumab
Objective Tumor Response Throughout the Study7
SecondaryTime to Initial Objective Response

Time from date of enrollment to first objective response; participants with stable disease at their last evaluable assessment date were censored at this date and participants with progressive disease while on study were censored after the last response was observed for all participants.

Time frame:
From enrollment until the data cut-off date of 22 December 2006. The median follow-up time was 36 weeks.
Reported as:
Median · weeks
Time to Initial Objective Response
weeksPanitumumab
Time to Initial Objective Response11 (7 to 23)
SecondaryProgression-free Survival Time

Kaplan-Meier estimate of median time from date of enrollment to date of first observed progression or death (whichever comes first); participants who did not progress while on study and did not die while on study were censored at their last evaluable assessment date.

Time frame:
From enrollment until the data cut-off date of 22 December 2006. The median follow-up time was 36 weeks.
Reported as:
Median · weeks
Progression-free Survival Time
weeksPanitumumab
Progression-free Survival Time8.1 (7.4 to 11.3)
SecondaryTime to Disease Progression

Kaplan-Meier estimate of median time from date of enrollment to date of first observed progression or death date if the death was due to disease progression (whichever comes first); participants who have not progressed while on study or died for reasons other than disease progression while on study were censored at their last evaluable assessment date.

Time frame:
From enrollment until the data cut-off date of 22 December 2006. The median follow-up time was 36 weeks.
Reported as:
Median · weeks
Time to Disease Progression
weeksPanitumumab
Time to Disease Progression8.3 (7.4 to 11.3)
SecondaryTime to Treatment Failure

Kaplan-Meier estimate of median time from date of enrollment to date decision was made to end the treatment phase for any reason; participants who complete the treatment phase or who remain in the treatment phase at the completion of the study were censored at this time.

Time frame:
From enrollment until the data cut-off date of 22 December 2006. The median follow-up time was 36 weeks.
Reported as:
Median · weeks
Time to Treatment Failure
weeksPanitumumab
Time to Treatment Failure8.4 (8.1 to 11.3)
SecondaryDuration of Stable Disease

Kaplan-Meier estimate of median time from date of enrollment to date of first observed progression or death date if the death was due to disease progression (whichever comes first); in those participants who had a best response of stable disease. Stable Disease is defined as neither sufficient shrinkage of index lesions to qualify for a partial response nor sufficient increase to qualify for progressive disease taking as reference the nadir sum of the products of the longest diameters since the treatment started.

Time frame:
From enrollment until the data cut-off date of 22 December 2006. The median follow-up time was 36 weeks.
Reported as:
Median · weeks
Duration of Stable Disease
weeksPanitumumab
Duration of Stable Disease16.0 (15.3 to 22.9)
SecondaryOverall Survival

Kaplan-Meier estimate of time to death from any cause; participants who had not died while on study or were lost to follow-up were censored at their last contact date.

Time frame:
From enrollment until the data cut-off date of 22 December 2006. The median follow-up time was 36 weeks.
Reported as:
Median · months
Overall Survival
monthsPanitumumab
Overall Survival9.0 (8.1 to 11.2)

Adverse events

Collected over First dose date through the safety follow-up visit. The median time frame is 2.6 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Panitumumab—61/203 (30%)200/203 (98.5%)
Most frequent serious events
Showing 10 of 65
Most frequent serious events
EventPanitumumab
Abdominal painGastrointestinal disorders6/203
DehydrationMetabolism and nutrition disorders6/203
Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)6/203
Colorectal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)6/203
DyspnoeaRespiratory, thoracic and mediastinal disorders6/203
Colon cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps)5/203
NauseaGastrointestinal disorders4/203
PyrexiaGeneral disorders4/203
Back painMusculoskeletal and connective tissue disorders4/203
Colorectal cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps)4/203
Most frequent other events
Showing 10 of 44
Most frequent other events
EventPanitumumab
DERMATITIS ACNEIFORMSkin and subcutaneous tissue disorders141/203
PRURITUSSkin and subcutaneous tissue disorders140/203
ERYTHEMASkin and subcutaneous tissue disorders137/203
FATIGUEGeneral disorders71/203
NAUSEAGastrointestinal disorders68/203
RASHSkin and subcutaneous tissue disorders59/203
DIARRHOEAGastrointestinal disorders55/203
VOMITINGGastrointestinal disorders53/203
EXFOLIATIVE RASHSkin and subcutaneous tissue disorders48/203
ANOREXIAMetabolism and nutrition disorders44/203

Baseline characteristics

Age, Continuous
Age, Continuous(years)Panitumumab
Median62 (54 to 68)
Sex: Female, Male
Sex: Female, Male(Participants)Panitumumab
Female89
Male114
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Panitumumab
American Indian or Alaska Native2
Asian3
Black or African American34
Hispanic or Latino13
White or Caucasian151
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Liao MZ, Prenen H, Dutta S, Upreti VV. The impact of hepatic and renal function on panitumumab exposures in patients with metastatic RAS wild-type colorectal cancer. Cancer Chemother Pharmacol. 2021 Oct;88(4):665-672. doi: 10.1007/s00280-021-04319-w. Epub 2021 Jul 2. PubMed 34213592 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2004 to primary completion in Jan 2007, 29 months.

Results were first posted in Dec 2013, 6 years 11 months after primary completion.

Of 120 industry-sponsored phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 72. This study's 29 months is below that.

Counting every sponsor, half of 618 studies reached it within 49 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 9, 2004
First posted
Aug 11, 2004
StartActual
Aug 1, 2004
Primary completionActual
Jan 1, 2007
CompletionActual
Aug 1, 2008
Results first posted
Dec 5, 2013
Last update
Nov 7, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 7, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00089635
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Aug 11, 2004
Start date
Aug 1, 2004
Primary completion
Jan 1, 2007
Completion
Aug 1, 2008
Results posted
Dec 5, 2013
Last update
Nov 7, 2022

Study contacts

MD
study director · Amgen
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Panitumumab

Start the discussion